IMAXIO is an integrated biotech company focused on immunology. It owns a pipeline of vaccines composed marketed, clinical-stage and preclinical-stage products:
Marketed pharmaceuticals: a vaccine against human leptospirosis marketed in France.
R&D pipeline based on the IMX313 technology platform: two clinical-stage projects and several preclinical-stage candidates, based on an antigen re-engineering platform to improve their immunogenicity, to develop more effective vaccines & immunotherapies.
IMAXIO’s main objective is to develop its R&D projects up to phase I / phase II clinical trials, and then out-licensed them to biopharmaceutical companies for phase III development and commercialization. IMAXIO remains open to new collaborations, for partners who are seeking technologies to improve the immune response on otherwise poorly immunogenic antigens.
IMAXIO was created in 2000 as a spin-off of the Medical Research Council and the University of Cambridge (United-Kingdom).
Marketed pharmaceuticals: a vaccine against human leptospirosis marketed in France.
R&D pipeline based on the IMX313 technology platform: two clinical-stage projects and several preclinical-stage candidates, based on an antigen re-engineering platform to improve their immunogenicity, to develop more effective vaccines & immunotherapies.
IMAXIO’s main objective is to develop its R&D projects up to phase I / phase II clinical trials, and then out-licensed them to biopharmaceutical companies for phase III development and commercialization. IMAXIO remains open to new collaborations, for partners who are seeking technologies to improve the immune response on otherwise poorly immunogenic antigens.
IMAXIO was created in 2000 as a spin-off of the Medical Research Council and the University of Cambridge (United-Kingdom).
